RNA-seq analysis reveals significant effects of EGFR signalling on the secretome of mesenchymal stem cells

Oncotarget

Volumn 5, Issue 21, 2014, Pages 10518-10528

  De Luca, Antonella ^a   Roma, Cristin ^a   Gallo, Marianna ^a   Fenizia, Francesca ^a   Bergantino, Francesca ^a   Frezzetti, Daniela ^a   Costantini, Susan ^a   Normanno, Nicola ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

EGFR; Mesenchymal stem cells; RNA seq; Tumor microenvironment

Indexed keywords

CD70 ANTIGEN; COMPLEMENTARY DNA; CXCL3 CHEMOKINE; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE INHIBITOR 1A; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR 10; GROWTH DIFFERENTIATION FACTOR 15; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; INTERLEUKIN 12 RECEPTOR BETA1; INTERLEUKIN 17; INTERLEUKIN 18 RECEPTOR ALPHA; INTERLEUKIN 19; INTERLEUKIN 1BETA; INTERLEUKIN 20; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7 RECEPTOR; LEUKEMIA INHIBITORY FACTOR RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; NERVE GROWTH FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA3; TRANSIENT RECEPTOR POTENTIAL CHANNEL; VASCULOTROPIN A; CHEMOKINE; CYTOKINE; EGFR PROTEIN, HUMAN; MESSENGER RNA; TUMOR MARKER; VEGFA PROTEIN, HUMAN;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DOWN REGULATION; EXON; GENE EXPRESSION; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; RNA SEQUENCE; RNA SPLICING; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; STOP CODON; UPREGULATION; BONE MARROW; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; FEMALE; GENETICS; HIGH THROUGHPUT SEQUENCING; MESENCHYMAL STROMA CELL; METABOLISM; PROCEDURES; PROTEIN MICROARRAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECRETION (PROCESS); WESTERN BLOTTING;

BIOMARKERS, TUMOR; BLOTTING, WESTERN; BONE MARROW; CELLS, CULTURED; CHEMOKINES; CYTOKINES; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MESENCHYMAL STROMAL CELLS; PROTEIN ARRAY ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84916888907     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2420     Document Type: Article

References (40)

1. El-Haibi CP, Karnoub AE. Mesenchymal stem cells in the pathogenesis and therapy of breast cancer. J Mammary Gland Biol Neoplasia. 2010; 15:399-409.
2. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007; 449:557-563.
3. Molloy AP, Martin FT, Dwyer RM, Griffin TP, Murphy M, Barry FP, O'Brien T, Kerin MJ. Mesenchymal stem cell secretion of chemokines during differentiation into osteoblasts, and their potential role in mediating interactions with breast cancer cells. Int J Cancer. 2009; 124:326-332.
4. Goldstein RH, Reagan MR, Anderson K, Kaplan DL, Rosenblatt M. Human bone marrow-derived MSCs can home to orthotopic breast cancer tumors and promote bone metastasis. Cancer Res. 2010; 70:10044-10050.
5. Chaturvedi P, Gilkes DM, Wong CC, Luo W, Zhang H, Wei H, Takano N, Schito L, Levchenko A, Semenza GL. Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis. J Clin Invest. 2013; 123:189-205.
6. De Luca A, Lamura L, Gallo M, Maffia V, Normanno N. Mesenchymal stem cell-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration. J Cell Biochem. 2012; 113:3363-3370.
7. Normanno N, Bianco C, Strizzi L, Mancino M, Maiello MR, De Luca A, Caponigro F, Salomon DS. The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets. 2005; 6:243-257.
8. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006; 7:505-516.
9. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006; 366:2-16.
10. Normanno N, Bianco C, De Luca A, Salomon DS. The role of EGF-related peptides in tumor growth. Front Biosci. 2001; 6:D685-707.
11. Waterman H, Sabanai I, Geiger B, Yarden Y. Alternative intracellular routing of ErbB receptors may determine signaling potency. J Biol Chem. 1998; 273:13819-13827.
12. Wilson KJ, Mill C, Lambert S, Buchman J, Wilson TR, Hernandez-Gordillo V, Gallo RM, Ades LM, Settleman J, Riese DJ 2nd. EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling. Growth Factors. 2012; 30:107-116.
13. McIntyre E, Blackburn E, Brown PJ, Johnson CG, Gullick WJ. The complete family of epidermal growth factor receptors and their ligands are co-ordinately expressed in breast cancer. Breast Cancer Res Treat. 2010; 122:105-110.
14. Satomura K, Derubeis AR, Fedarko NS, Ibaraki-O'Connor K, Kuznetsov SA, Rowe DW, Young MF, Gehron Robey P. Receptor tyrosine kinase expression in human bone marrow stromal cells. J Cell Physiol. 1998; 177: 426-438.
15. De Luca A, Gallo M, Aldinucci D, Ribatti D, Lamura L, D'Alessio A, De Filippi R, Pinto A, Normanno N. Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells. J Cell Physiol. 2011; 226:2131-2138.
16. Normanno N, De Luca A, Aldinucci D, Maiello MR, Mancino M, D'Antonio A, De Filippi R, Pinto A. Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. Endocr Relat Cancer. 2005; 12:471-482.
17. De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D, Pinto A, Normanno N. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol. 2008; 214:559-567.
18. Wang Y, Weil BR, Herrmann JL, Abarbanell AM, Tan J, Markel TA, Kelly ML, Meldrum DR. MEK, p38, and PI-3K mediate cross talk between EGFR and TNFR in enhancing hepatocyte growth factor production from human mesenchymal stem cells. Am J Physiol Cell Physiol. 2009; 297:C1284-1293.
19. Kerpedjieva SS, Kim DS, Barbeau DJ, Tamama K. EGFR ligands drive multipotential stromal cells to produce multiple growth factors and cytokines via early growth response-1. Stem Cells Dev. 2012; 21:2541-2551.
20. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009; 10:57-63.
21. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods. 2008; 5:621-628.
22. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010; 11:R106.
23. Oltean S, Bates DO. Hallmarks of alternative splicing in cancer. Oncogene. 2013.
24. Amit I, Citri A, Shay T, Lu Y, Katz M, Zhang F, Tarcic G, Siwak D, Lahad J, Jacob-Hirsch J, Amariglio N, Vaisman N, Segal E, Rechavi G, Alon U Mills GB, et al. A module of negative feedback regulators defines growth factor signaling. Nat Genet. 2007; 39:503-512.
25. Avraham R, Yarden Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol. 2011; 12:104-117.
26. Ara T, Declerck YA. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer. 2010; 46:1223-1231.
27. Dhingra K, Sahin A, Emami K, Hortobagyi GN, Estrov Z. Expression of leukemia inhibitory factor and its receptor in breast cancer: a potential autocrine and paracrine growth regulatory mechanism. Breast Cancer Res Treat. 1998; 48:165-174.
28. Rhee DK, Park SH, Jang YK. Molecular signatures associated with transformation and progression to breast cancer in the isogenic MCF10 model. Genomics. 2008; 92:419-428.
29. Dolle L, El Yazidi-Belkoura I, Adriaenssens E, Nurcombe V, Hondermarck H. Nerve growth factor overexpression and autocrine loop in breast cancer cells. Oncogene. 2003; 22:5592-5601.
30. Yu Y, Xiao CH, Tan LD, Wang QS, Li XQ, Feng YM. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-beta signalling. British journal of cancer. 2014; 110:724-732.
31. Marioni JC, Mason CE, Mane SM, Stephens M, Gilad Y. RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. Genome Res. 2008; 18:1509-1517.
32. Martin JA, Wang Z. Next-generation transcriptome assembly. Nat Rev Genet. 2011; 12:671-682.
33. Arcondeguy T, Lacazette E, Millevoi S, Prats H, Touriol C. VEGF-A mRNA processing, stability and translation: a paradigm for intricate regulation of gene expression at the post-transcriptional level. Nucleic Acids Res. 2013; 41:7997-8010.
34. Grunewald FS, Prota AE, Giese A, Ballmer-Hofer K. Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling. Biochim Biophys Acta. 2010; 1804:567-580.
35. Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer. 2008; 8: 880-887.
36. Zhang HT, Scott PA, Morbidelli L, Peak S, Moore J, Turley H, Harris AL, Ziche M, Bicknell R. The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br J Cancer. 2000; 83:63-68.
37. Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012; 136:331-345.
38. Sansone P, Bromberg J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol. 2012; 30:1005-1014.
39. Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012; 16:103-119.
40. Swartz MA, Iida N, Roberts EW, Sangaletti S, Wong MH, Yull FE, Coussens LM, Declerck YA. Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy. Cancer Res. 2012.